750 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers

• Lei Zheng,
• Jun Gong,
• John Powderly,
• Tanios Bekaii-Saab,
• Angela Alistar,
• Siqing Fu,
• Nashat Gabrail,
• Dae Won Kim,
• Yvonne Saenger,
• Olatunji Alese,
• Apollina Goel,
• Nataliya Uboha,
• Laura Agensky,
• Matteo Levisetti,
• Steven Margossian,
• Steve Quayle,
• J Eva Selfridge,
• Jorge Chaves,
• Jin Zhaohui

Affiliations

Lei Zheng

The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA

Jun Gong

1 Department of Gastrointestinal Malignancies, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA

John Powderly

10Carolina Biooncology Institute, Huntersville, NC, USA

Tanios Bekaii-Saab

Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ, USA

Angela Alistar

2Atlantic Health System, Morristown, NJ, USA

Siqing Fu

Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Nashat Gabrail

Department of Oncology, Gabrail Cancer Center, Canton, Ohio, USA

Dae Won Kim

7Moffitt Cancer Center, Tampa, FL, USA

Yvonne Saenger

5Columbia University Irving Medical Center/New York Presbyterian, New York, NY, USA

Olatunji Alese

1Winship Cancer Institute of Emory University, Decatur, GA, USA

Apollina Goel

1Invicro, a Konica Minolta Company, Boston, MA, USA

Nataliya Uboha

Department of Medicine, Section of Hematology and Oncology, University of Wisconsin, Carbone Cancer Center, Madison, Wisconsin, USA

Laura Agensky

15Cue Biopharma, Boston, MA, USA

Matteo Levisetti

15Cue Biopharma Inc, Cambridge, MA, USA

Steven Margossian

15Cue Biopharma, Boston, MA, USA

Steve Quayle

15Cue Biopharma Inc, Cambridge, MA, USA

J Eva Selfridge

5UH Cleveland, Cleveland, OH, USA

Jorge Chaves

4Northwest Medical Specialties, Tacoma, WA, USA

Jin Zhaohui

12Mayo Clinic, Rochester, MN, USA